| Budget Amount *help |
¥43,810,000 (Direct Cost: ¥33,700,000、Indirect Cost: ¥10,110,000)
Fiscal Year 2018: ¥8,580,000 (Direct Cost: ¥6,600,000、Indirect Cost: ¥1,980,000)
Fiscal Year 2017: ¥8,580,000 (Direct Cost: ¥6,600,000、Indirect Cost: ¥1,980,000)
Fiscal Year 2016: ¥8,580,000 (Direct Cost: ¥6,600,000、Indirect Cost: ¥1,980,000)
Fiscal Year 2015: ¥8,580,000 (Direct Cost: ¥6,600,000、Indirect Cost: ¥1,980,000)
Fiscal Year 2014: ¥9,490,000 (Direct Cost: ¥7,300,000、Indirect Cost: ¥2,190,000)
|
|---|
| Outline of Final Research Achievements |
This study aimed to develop biomarker proteins for early diagnosis and pathologic diagnosis for heart failure which has been regarded as a national disease, and the following useful diagnostic method by creating a high-affinity antibody. From this viewpoint, based on our findings obtained by proteomic analysis using the serum before and after the heart, the representative found that cytoskeletal proteins can be a heart failure biomarker in humans. Furthermore, we revealed that this candidate protein might suppress myocardial cell death in an ischemic-like condition. In the future, we will investigate the usefulness of this candidate protein as a heart failure biomarker by assessing the samples of heart failure patient of many cases in comparison with information of patient's disease state history.
|
